• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Regulatory press release18.06.2026 klo 12.08

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release18.06.2026 klo 01.27

Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

Zelluna
Regulatory press release18.06.2026 klo 01.21

Zelluna ASA: Private Placement and Retail Offering successfully placed

Zelluna

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release17.06.2026 klo 17.46

Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data

Zelluna
Regulatory press release07.05.2026 klo 08.00

Zelluna ASA: First Quarter 2026 results

Zelluna
Regulatory press release07.05.2026 klo 00.18

Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution

Zelluna
Regulatory press release04.05.2026 klo 18.58

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)

Zelluna
Regulatory press release04.05.2026 klo 16.19

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation

Zelluna
Press release27.04.2026 klo 08.07

BioStock: Zelluna entering the clinic with promising TCR-NK therapy

Zelluna
Regulatory press release23.04.2026 klo 10.37

Zelluna ASA – Annual General Meeting held on April 23, 2026

Zelluna
Regulatory press release08.04.2026 klo 12.25

Zelluna ASA - Disclosure of voting rights of Annual General Meeting

Zelluna
Regulatory press release08.04.2026 klo 12.25

Zelluna ASA – Disclosure of voting rights of Annual General Meeting

Zelluna
Regulatory press release27.03.2026 klo 11.01

Zelluna ASA – Mandatory notification of trade

Zelluna
Regulatory press release26.03.2026 klo 16.28

ZLNA: Zelluna to host Capital Markets Update 2026

Zelluna
Regulatory press release26.03.2026 klo 16.28

Zelluna to host Capital Markets Update 2026

Zelluna
Regulatory press release26.03.2026 klo 09.56

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna
Regulatory press release25.03.2026 klo 08.00

Zelluna ASA [ZLNA]: Annual Report 2025

Zelluna
Regulatory press release09.03.2026 klo 09.00

ZLNA: Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Zelluna
Regulatory press release09.03.2026 klo 09.00

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Zelluna
Regulatory press release20.02.2026 klo 15.30

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Zelluna